Flag of the European Union EU Clinical Trials Register Help

Clinical trials for COVID-19

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    21 result(s) found for: COVID-19. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2021-000291-11 Sponsor Protocol Number: IMRES Start Date*: 2021-05-30
    Sponsor Name:Medical University of Vienna
    Full Title: Characterization of immune responsiveness after SARS-CoV-2 Vaccination in patients with Immunodeficiency or immunosuppressive therapy (COVID-19)
    Medical condition: Vaccination against SARS-CoV-2 in immunocompromised patients
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004865 10084462 SARS-CoV-2 vaccination LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-001682-12 Sponsor Protocol Number: MYOFLAME-19 Start Date*: 2023-06-16
    Sponsor Name:Goethe University Frankfurt
    Full Title: Randomised placebo controlled clinical trial of efficacy of MYOcardial protection with postacute inFLAMmatory cardiac involvEment due to COVID-19 (MYOFLAME-19)
    Medical condition: Inflammatory cardiovascular involvement due to COVID-19, defined by Cardiovascular magnetic resonance imaging
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    20.0 10007541 - Cardiac disorders 10007650 Cardiovascular disorder NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000623-13 Sponsor Protocol Number: VIR-7831-5008 Start Date*: 2021-07-29
    Sponsor Name:Vir Biotechnology, Inc.
    Full Title: A Phase 3 randomized, multi-center, open label study to assess the efficacy, safety, and tolerability of monoclonal antibody VIR-7831 (sotrovimab) given intramuscularly versus intravenously for the...
    Medical condition: Mild/moderate COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10084268 COVID-19 PT
    23.1 10021881 - Infections and infestations 10084401 COVID-19 respiratory infection LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) AT (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-001172-15 Sponsor Protocol Number: APN01-01-COVID19 Start Date*: 2020-04-08
    Sponsor Name:APEIRON Biologics AG
    Full Title: Recombinant human angiotensin-converting enzyme 2 (rhACE2) as a treat-ment for patients with COVID-19
    Medical condition: Severe COVID-19 POSITIVE hospitalized male or female, between 18 and ≤ 80 years of age
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) AT (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2022-003452-14 Sponsor Protocol Number: SBC007C401 Start Date*: 2023-05-02
    Sponsor Name:Berlin Cures GmbH
    Full Title: A prospective, double-blind, randomised, parallel group, placebo controlled, multicentre, Phase II study to investigate the efficacy, GPCR autoantibody neutralising effect, safety, and tolerability...
    Medical condition: long Covid
    Disease: Version SOC Term Classification Code Term Level
    25.1 10021881 - Infections and infestations 10087832 COVID-19 rebound LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) AT (Completed) FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001411-25 Sponsor Protocol Number: XPORT-COV-1001 Start Date*: 2020-05-18
    Sponsor Name:Karyopharm Therapeutics Inc.
    Full Title: A Phase 2 Randomized Single-Blind Study to Evaluate the Activity and Safety of Low Dose Oral Selinexor (KPT-330) in Patients with Severe COVID-19 Infection
    Medical condition: Severe COVID-19 Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10051905 Coronavirus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) AT (Completed) GB (GB - no longer in EU/EEA) ES (Temporarily Halted) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003898-94 Sponsor Protocol Number: BN40955 Start Date*: 2019-03-07
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH HUNTINGTON’S DISEASE
    Medical condition: Huntington's disease (HD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Completed) NL (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000498-15 Sponsor Protocol Number: RXC007/0002 Start Date*: 2022-10-04
    Sponsor Name:Redx Pharma plc
    Full Title: A Multi-Cohort, Randomised, Placebo-Controlled Phase 2a Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Ascending Doses of RXC007 in Patients with Idiopathic...
    Medical condition: Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10067761 Exacerbation of idiopathic pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) CZ (Completed) ES (Ongoing) HU (Completed) AT (Ongoing) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-002844-66 Sponsor Protocol Number: INCB50465-309 Start Date*: 2022-05-30
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants with Primary Warm Autoimmune Hemolytic Anemia (PATHWAY)
    Medical condition: Primary Warm Autoimmune Hemolytic Anemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed) ES (Ongoing) NL (Completed) HU (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-000954-67 Sponsor Protocol Number: ATB200-07 Start Date*: 2020-04-08
    Sponsor Name:Amicus Therapeutics, Inc.
    Full Title: A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease
    Medical condition: Adult Subjects With Late Onset Pompe Disease (LOPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10075702 Pompe's disease late onset LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) DE (Completed) DK (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) GR (Trial now transitioned) SI (Trial now transitioned) AT (Completed) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002913-16 Sponsor Protocol Number: 0135-0347 Start Date*: 2020-11-26
    Sponsor Name:SCS Boehringer Ingelheim Comm. V
    Full Title: The TRISTARDS trial - ThRombolysIS Therapy for ARDS A Phase IIb/III operationally seamless, open-label, randomised, sequential, parallel-group adaptive study to evaluate the efficacy and safety of ...
    Medical condition: Acute respiratory distress syndrome caused by Covid-19
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Prematurely Ended) AT (Ongoing) PT (Completed) NL (Completed) FR (Completed) DK (Prematurely Ended) IT (Prematurely Ended) PL (Completed) RO (Ongoing) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-000936-23 Sponsor Protocol Number: C20-15 Start Date*: 2020-03-09
    Sponsor Name:INSERM
    Full Title: Multi-centre, adaptive, randomized trial of the safety and efficacy of treatments of COVID-19 in hospitalized adults
    Medical condition: COVID-19 - Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen < 72 hours prior to randomization. - Illness of any durat...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) AT (Completed) PT (Completed) SK (Completed) CZ (Completed) NO (Prematurely Ended) IE (Prematurely Ended) HU (Completed) ES (Ongoing) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000541-41 Sponsor Protocol Number: N/A Start Date*: 2021-04-22
    Sponsor Name:Oslo University Hospital
    Full Title: European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial
    Medical condition: SARS-CoV-2- infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) BE (Trial now transitioned) DE (Trial now transitioned) HU (Trial now transitioned) SK (Trial now transitioned) IE (Trial now transitioned) PT (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004676-22 Sponsor Protocol Number: M16-066 Start Date*: 2019-01-14
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) SK (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) SE (Trial now transitioned) NL (Trial now transitioned) DK (Completed) GR (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) LT (Trial now transitioned) PT (Trial now transitioned) GB (GB - no longer in EU/EEA) LV (Trial now transitioned) SI (Trial now transitioned) BG (Trial now transitioned) HR (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-004726-34 Sponsor Protocol Number: SHP620-302 Start Date*: 2017-09-01
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegaloviru...
    Medical condition: Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10021819 Infection in marrow transplant recipients LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) CZ (Completed) PL (Completed) FR (Completed) HR (Completed) IT (Completed) GR (Completed) AT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-001910-13 Sponsor Protocol Number: AV-101-002 Start Date*: 2022-02-21
    Sponsor Name:Aerovate Therapeutics, Inc.
    Full Title: IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hy...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10077729 Pulmonary arterial hypertension WHO functional class III LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10077730 Pulmonary arterial hypertension WHO functional class IV LLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10077740 Pulmonary arterial hypertension WHO functional class II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) GR (Trial now transitioned) PT (Trial now transitioned) IE (Trial now transitioned) AT (Trial now transitioned) LV (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001540-56 Sponsor Protocol Number: 208657 Start Date*: 2019-08-18
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A multi-center, randomized, double-blind, parallel-group, placebo controlled study of mepolizumab 100 mg SC as add-on treatment in participants with COPD experiencing frequent exacerbations and cha...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) HU (Completed) ES (Ongoing) NL (Completed) DK (Completed) BE (Completed) DE (Completed) SE (Completed) IE (Completed) IT (Completed) GR (Completed) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-004703-51 Sponsor Protocol Number: COMB157G2399 Start Date*: 2019-01-10
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) SK (Trial now transitioned) HU (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Trial now transitioned) AT (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) ES (Ongoing) CZ (Trial now transitioned) SE (Trial now transitioned) LT (Trial now transitioned) DK (Trial now transitioned) FI (Trial now transitioned) NO (Trial now transitioned) BE (Trial now transitioned) LV (Trial now transitioned) GR (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-000674-38 Sponsor Protocol Number: M14-533 Start Date*: 2016-09-20
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis (UC)
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10009900 Colitis ulcerative PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) AT (Trial now transitioned) FI (Trial now transitioned) PL (Completed) SE (Completed) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) LV (Trial now transitioned) GR (Trial now transitioned) EE (Trial now transitioned) IE (Trial now transitioned) HU (Trial now transitioned) PT (Trial now transitioned) LT (Trial now transitioned) BE (Trial now transitioned) NO (Trial now transitioned) ES (Ongoing) HR (Trial now transitioned) IT (Trial now transitioned) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002937-31 Sponsor Protocol Number: MA30143 Start Date*: 2017-09-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis
    Medical condition: Relapsing remitting multiple sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10028245 Multiple sclerosis PT
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    20.0 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    20.1 10029205 - Nervous system disorders 10039720 Sclerosis multiple LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NO (Completed) SE (Completed) AT (Completed) DK (Completed) DE (Completed) PT (Completed) BE (Completed) HU (Completed) PL (Completed) SK (Completed) ES (Ongoing) BG (Completed) SI (Completed) NL (Completed) GB (GB - no longer in EU/EEA) FR (Ongoing) HR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 11:51:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA